OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, includin… Read more
OnKure Therapeutics, Inc. (OKUR) - Total Assets
Latest total assets as of September 2025: $72.83 Million USD
Based on the latest financial reports, OnKure Therapeutics, Inc. (OKUR) holds total assets worth $72.83 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
OnKure Therapeutics, Inc. - Total Assets Trend (2020–2024)
This chart illustrates how OnKure Therapeutics, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
OnKure Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
OnKure Therapeutics, Inc.'s total assets of $72.83 Million consist of 98.3% current assets and 1.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 96.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how OnKure Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OnKure Therapeutics, Inc.'s current assets represent 98.3% of total assets in 2024, a decrease from 99.7% in 2020.
- Cash Position: Cash and equivalents constituted 96.4% of total assets in 2024, down from 97.1% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
OnKure Therapeutics, Inc. Competitors by Total Assets
Key competitors of OnKure Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
OnKure Therapeutics, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - OnKure Therapeutics, Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - OnKure Therapeutics, Inc. is currently not profitable relative to its asset base.
OnKure Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.45 | 23.71 | 10.65 |
| Quick Ratio | 11.45 | 23.71 | 10.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $65.28 Million | $ 73.75 Million | $ 132.58 Million |
OnKure Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between OnKure Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.49 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | 221.6% |
| Total Assets | $114.91 Million |
| Market Capitalization | $20.01 Million USD |
Valuation Analysis
Below Book Valuation: The market values OnKure Therapeutics, Inc.'s assets below their book value (0.17 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: OnKure Therapeutics, Inc.'s assets grew by 221.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for OnKure Therapeutics, Inc. (2020–2024)
The table below shows the annual total assets of OnKure Therapeutics, Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $114.91 Million | +221.56% |
| 2023-12-31 | $35.73 Million | +123.35% |
| 2022-12-31 | $16.00 Million | -89.61% |
| 2021-12-31 | $154.02 Million | +178.92% |
| 2020-12-31 | $55.22 Million | -- |